Explore the words cloud of the RV001 project. It provides you a very rough idea of what is the project "RV001" about.
The following table provides information about the project.
Coordinator |
RHOVAC APS
Organization address contact info |
Coordinator Country | Denmark [DK] |
Project website | https://www.rhovac.com/ |
Total cost | 71˙429 € |
EC max contribution | 50˙000 € (70%) |
Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
Code Call | H2020-SMEInst-2018-2020-1 |
Funding Scheme | SME-1 |
Starting year | 2018 |
Duration (year-month-day) | from 2018-04-01 to 2018-09-30 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | RHOVAC APS | DK (HORSHOLM) | coordinator | 50˙000.00 |
Prostate cancer is the most commonly diagnosed cancer among men, with an anticipated 1.7M new cases and 499,000 deaths by 2030 worldwide. Although, most cancer therapies available focus on treatment of the primary tumor, the leading cause of cancer morbidity and mortality is metastasis. Today’s current treatments for metastatic prostate cancer focus on later stage of the cancer progression, when the signs of metastasis spread are already observed; and modestly prolong the patient’s survival and have serious side effects. Therefore, there is a high unmet need for new therapies, which can effectively address the problem as the first adjuvant treatment against early stage of metastasis in prostate cancer. RhoVac is a biotechnology company dedicated to the research and development of immunotherapies for the treatment of early stage metastatic cancer. The RV001 (RhoVac’s first product) vaccine is the first therapeutic vaccine against metastatic cancer cells, specifically targeting the prevention of cancer relapses. The concept behind RV001 relies on the reprogramming of the patient own T cells to recognise and eliminate early stage metastatic cancer cells. Together with an unprecedented therapeutic potential in multiple cancer types, RV001 holds important competitive advantages, such as safety, tolerability and cost-effectiveness. However, to secure swift development and successful commercialization, RhoVac needs partnerships and capital to achieve RV001 clinical validation. In this context, we believe SME instrument will be crucial to position RV001 within the metastatic cancer treatment and to confirm the high pharma-economic value of our disruptive technology. The accomplishment of SME Phase 1 and Phase 2 project objectives will maximize the clinical value of our vaccine within the selected market and a lead to a significant business opportunity for RhoVac – revenues are expected to be around €350M, within 5 years of market approval, only in prostate cancer segment.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RV001" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "RV001" are provided by the European Opendata Portal: CORDIS opendata.